Bright Minds Biosciences DRUG 深 滬
已收盤 08-07 16:00:00 美东时间
79.33
-1.470
-1.82%
華盛通- 最 高83.00
- 今 開81.67
- 成交量 15.64万股
- 最 低 78.00
- 昨 收 80.80
- 總市值 7.78亿
- 52周最高 123.75
- 市盈率 靜 --
- 換手率 1.59%
- 52周最低 38.0001
- 委 比 92.31%
- 總股本 981.21万
- 歷史最高 123.75
- 量 比 0.86
- 振 幅 6.19%
- 歷史最低 0.93
- 每 手 1
- 風險率 14.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vistagen Appoints Douglas J. Williamson to its Board of Directors
Vistagen appoints Douglas J. Williamson, MD, to its Board of Directors. With nearly 30 years of leadership experience in neuroscience drug development, clinical research, and regulatory strategy, Dr. Williamson will provide valuable insights as Vistagen advances its pipeline and evaluates growth opportunities. He previously served as Chief Medical Officer at QurAlis Corporation and held senior roles at Acadia Pharmaceuticals, Avadel Pharmaceutica...
07-31 12:30
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220
Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Overweight and raises the price target from $190 to $220.
05-21 01:28
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145
Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $145.
04-13 20:21
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
03-30 17:57
